AstraZeneca upbeat on 'groundbreaking' Enhertu results
20th Sep 2021 07:29
(Sharecast News) - AstraZeneca said on Monday that detailed positive results from the head-to-head 'DESTINY-Breast03' phase 3 trial showed that Enhertu, or trastuzumab deruxtecan, demonstrated superior progression-free survival compared to trastuzumab emtansine (T-DM1).
Read moreSunday newspaper round-up: Breast cancer, Food shortages, IAG
19th Sep 2021 14:30
(Sharecast News) - The trial of a new drug to treat an aggressive form of breast cancer has "shattered expectations" raising hopes of a "cure", according to its maker, AstraZeneca. The British pharmaceuticals company said three quarters of women in the trial of its new drug, Enhertu, had shown no progression in their disease after 12 months compared with just a third treated with a different medicine. - Sunday Times
Read moreAstraZeneca reports positive results from latest Imfinzi trial
9th Sep 2021 16:25
(Sharecast News) - AstraZeneca said on Thursday that positive results from the 'Poseidon' phase 3 trial showed 'Imfinzi', or durvalumab, and tremelimumab, when added to platinum-based chemotherapy, demonstrated a statistically-significant and clinically-meaningful improvement in overall survival and progression-free survival compared to chemotherapy alone in the first-line treatment of patients with stage four metastatic non-small cell lung cancer (NSCLC).
Read moreAstraZeneca asthma products perform well in phase 3 trials
9th Sep 2021 07:41
(Sharecast News) - AstraZeneca said on Thursday that positive high-level results from the 'MANDALA' and 'DENALI' phase 3 trials of PT027, or albuterol/budesonide, at both 180/160mcg and 180/80mcg doses, met all primary endpoints.
Read moreScientists to begin human trials of cancer vaccine using AstraZeneca technology
3rd Sep 2021 13:07
(Sharecast News) - Researchers in the UK and Germany will begin human trials for a therapeutic cancer vaccine "shortly" that uses the same technology as AstraZeneca's Covid-19 shot.
Read moreEU approves AstraZeneca blood disorder treatment for children
3rd Sep 2021 07:43
(Sharecast News) - AstraZeneca said its Ultomiris blood disorder treatment has been approved in the European Union for expanded use to include children and adolescents.
Read moreEMA says no urgent need yet for booster Covid-19 vaccine doses
2nd Sep 2021 17:43
(Sharecast News) - There is no urgent need to give healthy adults a third Covid-19 vaccine dose, Europe's health regulator said.
Read moreBerenberg raises target price on AstraZeneca
2nd Sep 2021 09:58
(Sharecast News) - Analysts at Berenberg raised their target price on drugmaker AstraZeneca from 9,500.0p to 10,000.0p on Thursday following the firm's second-quarter earnings results.
Read moreAstraZeneca upbeat on Wilson disease trial, Forxiga approval
26th Aug 2021 07:21
(Sharecast News) - AstraZeneca said on Thursday that positive high-level results from the 'FoCus' phase 3 trial in Wilson disease showed 'ALXN1840' met the primary endpoint, with a statistically significant improvement in daily mean copper mobilisation from tissues, demonstrating superiority compared with standard-of-care treatments.
Read moreAstraZeneca Covid antibody combination meets primary endpoint
20th Aug 2021 09:05
(Sharecast News) - AstraZeneca said on Friday that an antibody combination modified to potentially provide long-lasting protection against Covid-19 has met its primary endpoint in a trial.
Read moreAstraZeneca ends ALS trial on committee recommendation
20th Aug 2021 09:02
(Sharecast News) - AstraZeneca announced on Friday that its rare disease division Alexion is discontinuing 'CHAMPION-ALS', the global phase 3 clinical trial of 'Ultomiris', or ravulizumab, in adults with amyotrophic lateral sclerosis (ALS).
Read morePfizer and AstraZeneca vaccines less effective versus Delta, large UK study finds
19th Aug 2021 10:52
(Sharecast News) - The Delta variant of Covid-19 blunts the efficacy of the Pfizer-BioNTech and AstraZeneca vaccines, the results of one of the largest real-world studies revealed.
Read moreSunday newspaper round-up: Meggitt, GlaxoSmithKline, Luxury goods
15th Aug 2021 17:08
(Sharecast News) - Ministers must be prepared to block a takeover of Meggitt if any bidder tries to buy it without giving binding commitments on investment and jobs, the FTSE 250 aerospace and defence manufacturer's chairman warned this weekend. Sir Nigel Rudd said that while "clearly, price is important", any new owner would need to give Meggitt and the government undertakings, including to keep the company's headquarters in Coventry and maintain R&D spending. - Sunday Times
Read moreJP Morgan restarts AstraZeneca at overweight, sees re-rating opportunity
12th Aug 2021 12:11
(Sharecast News) - Analysts at JP Morgan resumed their coverage of AstraZeneca at 'overweight', telling clients they saw a "re-rating opportunity".
Read moreThursday broker round-up
12th Aug 2021 12:09
(Sharecast News) - Hill&Smith: Berenberg keeps at buy and raises target price from 1,775.0p to 1,995.0p.
Read more